| [1] |
Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in NCI's SEER program:suggesting a possible link between etiology and outcome [J]. Breast Cancer Res Treat, 2005,90(2):127-137.
|
| [2] |
Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation [J]. Nature Rev,2005,5(12):921-929.
|
| [3] |
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism[J]. Nature Rev, 2006,7(8);606-619.
|
| [4] |
Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol-3,4,5-trisphosphate and Akt/protein kinase B signaling pathway [J]. Proc Natl Acad Sci USA,1999,96(11):6199-6204.
|
| [5] |
Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3 - kinase mutations identified in human cancer are oncogenic [J].Proc Natl Acad Sci USA, 2005,102(3):802-807.
|
| [6] |
Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells [J]. Cancer Res,2005,65(23):10992-11000.
|
| [7] |
Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells [J]. Proc Natl Acad Sci USA,2005,102(51):18443-18448.
|
| [8] |
Alex T, Merav YL. Akt signaling and cancer: surviving but not moving on. Cancer Res, 2006,66(8):3963-3966.
|
| [9] |
Samuels Y, Diaz LA Jr , Schmidt-kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells[J]. Cancer Cell ,2005,7(6):561-573.
|
| [10] |
Guo XN, RajPut A, Rose R, et al. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model [J]. Cancer Res,2007,67(12):5851-5858.
|
| [11] |
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers [J]. Science,2004,304(5670):554-554.
|
| [12] |
Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers [J].Cancer Biol Ther,2004,3(8):772-775.
|
| [13] |
Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma [J]. Cancer Res 2005,65(7):2554-2559.
|
| [14] |
Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer [J]. Cancer Res,2004,64(21):7678-7681.
|
| [15] |
Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma [J]. J Pathol ,2006,208(3):350-355.
|
| [16] |
Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome [J]. Breast Cancer Res Treat, 2006;96(1):91-95.
|
| [17] |
Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women [J]. Clin Cancer Res,2007,13(2 Pt 1):408-414.
|
| [18] |
Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy [J]. Curr Cancer Drug Targets,2008,8(8):733-740.
|
| [19] |
Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation [J]. Nat Rev Cancer, 2005,5(12):921-929.
|
| [20] |
Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer [J]. J Cancer Res Clin Oncol,2010,136 (11):1657-1669.
|
| [21] |
Martin MB, Franke TF, Stoica GE, et al. A role for AKT inmediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I [J]. Endocrinology ,2000,141(12):4503-4511.
|
| [22] |
Perez Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer [J]. Clin Cancer Res ,2007,13(12):3577-3584.
|
| [23] |
Park BH, Davidson NE. PI3Kinase activation and response to trastuzumab therapy: what's neu with herceptin resistance[J]. Cancer Cell,2007 ,12(4):297-299.
|
| [24] |
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J]. Cancer Cell,2007,12(4):395-402.
|
| [25] |
Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines [J]. Ann Oncol,2010,21(2):255-262.
|
| [26] |
Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas [J]. Clin Cancer Res,2007,13(20):6064-6069.
|
| [27] |
Liedtke C, Cardone L, Tordai A, et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer [J]. Breast Cancer Res,2008,10(2):R27.
|
| [28] |
Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer [J]. Clin Cancer Res, 2009,15(16):5049-5059.
|
| [29] |
Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis [J]. Breast Cancer Res Treat,2010,122(1):45-53.
|
| [30] |
Di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a ‘‘good’’ activating mutation? [J]. Clin Cancer Res,2009,15(16):5017-5019.
|
| [31] |
Lerma E, Catasus L, Gallardo A, et al. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive)breast carcinomas [J]. Virchows Arch,2008,453(2):133-139.
|
| [32] |
Ellis MJ, Lin L, Crowder R, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer [J]. Breast Cancer Res Treat ,2010,119 (2):379-390.
|
| [33] |
Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns [J]. Hum Mutat,2008,29(2):284-288
|
| [34] |
Lai YL, Mau BL, Cheng WH, et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients [J]. Ann Surg Oncol,2008,15(4):1064-1069.
|
| [35] |
Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations [J]. Proc Natl Acad Sci USA ,2003,100(15): 8817-8822.
|
| [36] |
Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors[J]. Proc Natl Acad Sci USA,2005, 102(45): 16368-16373.
|
| [37] |
Crowder RJ, Phommaly C, Tao Y, et al . PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer [J]. Cancer Res,2009,69(9):3955 - 3962.
|